Rhinomed Limited (ASX:RNO) is a Melbourne based, medical technology firm with a focus on nasal, respiratory and breathing management technologies. The company is seeking to monetise applications of its technology portfolio in the Sport, Sleep, Wellbeing and Drug Delivery markets. For more information, go to www.rhinomed.global
Follow the Turbine on Twitter at @theturbinecom
Follow Mute Snoring on Twitter at @mutesnoring
Respiratory technology company Rhinomed Limited (ASX:RNO) (OTCMKTS:RHNMF) can report another strong quarter of growth. During the quarter the company shipped and invoiced $602k ($1.2m for the half year) worth of stock to retailers, consumers and distributors. This reflects the strength of the Company's growing global retail distribution base.
Rhinomed Limited (ASX:RNO) (OTCMKTS:RHNMF) a leading sleep and nasal respiratory technology company has successfully undertaken an AUD$3.6 million placement to institutional and sophisticated private investors at $0.15 per share.
Rhinomed Ltd (ASX:RNO) (OTCMKTS:RHNMF) provides the Company's latest Investor Presentation.
The Directors of Rhinomed Limited ASX:RNO) provide the following Report in relation to the Group for the year ended 30 June 2017.
A yellow nose ring matches the yellow jersey. Chris Froome, having taken his 4th Tour de France title continues to support yellow - in the form of an innovative sports breathing device called Turbine(TM).
Rhinomed Limited (ASX:RNO) (OTCMKTS:RHNMF), is pleased to announce that it has been advised that its sleep and breathing technology Mute, has been added to the annual 'large set' planogram produced by the Hamacher Resource Group, Inc.
Rhinomed Ltd (ASX:RNO) (OTCMKTS:RHNMF) are pleased to provide the Company's latest Investor Update for May 2017.
Respiratory technology company Rhinomed (ASX:RNO) (OTCMKTS:RHNMF) is pleased to announce that it has been advised by Sigma Healthcare (ASX:SIG) that Mute sleep technology will form part of the 2017 core range for the Amcal and Guardian pharmacy brands.
Respiratory technology company Rhinomed (ASX:RNO) (OTCMKTS:RHNMF) is pleased to announce further expansion of its North American retail distribution footprint having received confirmation that its Mute sleep technology will go on sale in 811 GNC Holdings Inc. health, wellness and performance stores.
Rhinomed (ASX:RNO) advises it has undertaken a AUD$2.19 million private placement to two US based sophisticated investor groups as part of its 15% placement capacity. In addition, the company has flagged its intention to hold a General Meeting to approve a capital management initiative that will seek to consolidate the company's capital and provide a sale of less than marketable share parcels facility.
Appendix 4C - quarterly and Business Update Becoming a substantial holder JMCB Change of Director's Interest Notice - MJ Change of Director's Interest Notice - RD Master Investor UK 2018 Presentation Becoming a substantial holder PS Becoming a substantial holder - PS Rhinomed to present at International Investor Conferences Change in Executive Remuneration Half Yearly Report and Accounts
